Olga Meystelman

Olga Meystelman is a seasoned professional in the field of quality management and regulatory affairs, currently serving as Director at March Biosciences since January 2025. Prior to this role, Olga worked as Associate Director at CTMC, a joint venture between Resilience and MD Anderson Cancer Center, from July 2022 to January 2025, and held a similar title at Merck from March 2020 to July 2022, focusing on Third Party Quality Management. Olga's career began at Celgene, where Olga progressed through various roles from Supervisor to Manager between February 2010 and March 2020. Education includes a Master of Science in Quality Assurance/Regulatory Affairs from Temple University (2013-2017) and a Bachelor's degree in Biology from the same institution, where studies began in 2004 and are ongoing.